A new market survey shows that ColdZyme® Mouth Spray is the cold product that pharmacy staff in Sweden recommend most. The majority of consumers who asked for help and recommendations at the pharmacy regarding colds were advised to use ColdZyme. In addition, recent statistics from Nielsen Data show that ColdZyme is the most successful brand launch of a new cold product in over 30 years. The product has achieved a market share of 5 % (value) in the cold category since its launch in Sweden in 2013.
Market research company GfK was commissioned by Enzymatica to conduct a market survey at
93 pharmacies in the Stockholm, Gothenburg and Skåne metropolitan areas. “Mystery shoppers” who pretended to be consumers with symptoms that included feeling sick and a sore throat asked pharmacy staff to recommend something that could help with a cold. ColdZyme was the product recommended more often than other cold products to prevent and shorten the duration of a cold. ColdZyme was recommended by 67 percent of pharmacy staff, while only 26 percent recommended the product that received the second highest number of votes. The results are statistically significant.
- Spraying in the mouth and throat causes a protective barrier to form on the mucosa. The barrier captures the cold virus and deactivates the ability of the virus to infect cells, which protects the throat and allows the body to rid itself of the virus naturally,” says Fredrik Lindberg, CEO of Enzymatica.
Typical occasions when the risk of being infected with colds increases include large family gatherings, train and air travel, at work in an open office landscape, or during typical cold periods such as the end of vacation, the start of school or the winter holiday season.
- Using the spray for prevention when you are exposed to an increased risk of contamination makes it possible to prevent a cold from breaking out. And if you’ve already caught a cold, the duration of disease can be reduced by using ColdZyme,” says Fredrik Lindberg.
Of the 5 best-selling brands within colds, ColdZyme is the only completely new brand to be launched in over 30 years. ColdZyme currently has a market share of 5 % (value), and is also the 5th best-selling brand in Sweden that is sold in the cold category in Swedish pharmacies (Nielsen Data, 20170930).
Enzymatica has conducted a number of user studies, including studies in which elite athletes and preschool and elder care staff have used ColdZyme. The results show findings such as a significant reduction in the number of sickness absence days and milder cold symptoms when participants in the studies did catch colds.
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB Tel: +46 (0)708-86 53 70 | Email: firstname.lastname@example.org
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company’s first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit:www.enzymatica.se.
Enzymatica’s certified adviser is Erik Penser Bank.
About Mystery Shopping
The © GfK Mystery Shopping and Attitudinal Study was conducted in April and May 2017. A total of 93 pharmacies were visited in the Stockholm, Gothenburg and Skåne metropolitan areas. The mystery shopper presented with symptoms such as feeling sick and/or a sore throat and asked for a product that could help. Mystery Shopping conducted by GfK shows that ColdZyme is recommended by pharmacists significantly (P <0.001) more often than other cold products to prevent or reduce the duration of a cold.
 © GfK Mystery Shopping and Attitudinal Study | May 2017
 Nielsen Data, 12M MAT, 20170930